The Caris Precision Oncology Alliance™ (POA) is a growing network of over 95 leading cancer centers and academic institutions, including over 45 NCI-designated comprehensive cancer centers across the country, collaborating to deliver molecular science solutions to promote clinical trials, deliver combined clinical-genomic data, collaborative research, and publications.
These collaborators share a commitment to precision medicine and work to:
As a member of the POA, the University of Colorado Cancer Center investigators have access to various methods of research support including:
Caris CODEai is the most comprehensive, real-world data platform integrating Caris’ extensive catalog of molecular data with cancer treatment information and clinical outcomes data for 295,000+ patients covering greater than one million data points per patient.
CODEai is a real-world clinico-genomic data platform that assists clinicians and researchers in the discovery of novel biomarkers as well as the confirmation of drug/biomarker associations. It features multiple data visualization tools to support cohort analysis based on user-defined search queries:
The Caris CODEai state-of-the-art informatics system and big data architecture provides an unprecedented resource for developing a better understanding of the molecular mechanisms of cancer.
To learn more about how to utilize the University of Colorado / Caris POA collaboration, click here.
As a POA member, there are a number of collaborative research opportunities that CU investigators can take part in.
Questions regarding research collaborations can be addressed by your local Caris team members.
Explore CODEai and develop project concept with Caris MSL.
As a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation, Caris is helping our partners improve cancer care and maximize patient outcomes through advanced diagnostic testing and molecular insights. Caris has a unique combination of expertise, proprietary technologies, clinical testing abilities and a vast library of data that allows Caris to collaboratively advance precision medicine in ways never before possible.
Caris molecular profiling technologies provide machine learning, artificial intelligence-driven offerings revolutionizing cancer care, in addition to analyzing DNA, RNA and proteins with multiple technologies (WES, WTS, IHC, ISH, PyroSeq, etc.).
Clinical Trial Solutions offers clinical trial enablement and biopharma collaborations through Right-In-Time trials.
Caris Molecular Tumor Board allows consults with cancer experts across the country to review molecular information on specific patient cases.
If you have additional questions or need assistance on any of the information provided, please reach out to: MedicalAffairs@CarisLS.com.